HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $16
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $15 to $16.
Despite Competition This Analyst Finds BrainsWay Attractive
Yesterday BrainsWay Ltd (NASDAQ:BWAY) reported Q2 sales of $8.0 million, up 14% Y/Y, missing the consensus of $8.47 million, amid a…
Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
LabCorp (LH) To Report Q2 Earnings: What’s In The Cards?
Laboratory Corporation of America Holdings (NYSE: LH), also known as LabCorp, is slated to report second-quarter 2022 results on Jul 28, before market open.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Neuronetics Reports Filed Federal Suit Against Brainsway For ‘Misleading Psychiatrists, Patients’
Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders,
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell
• REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million.
Earnings Preview: Brainsway
Brainsway (NASDAQ:BWAY) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement.
Analysts estimate that Brainsway will report an earnings per share (EPS) of $-0.07.
BrainsWay Announces Final Local Coverage Determination Issued By Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage Of Deep TMS For The Treatment Of OCD
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that a